Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3107)
All Articles published online
|
Jan 15, 2004 (publication date) through Apr 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Wan YL, Zheng SS, Zhao ZC, Li MW, Jia CK, Zhang H. Expression of co-stimulator 4-1BB molecule in hepatocellular carcinoma and adjacent non-tumor liver tissue, and its possible role in tumor immunity. World J Gastroenterol 2004; 10(2): 195-199 [PMID: 14716821 DOI: 10.3748/wjg.v10.i2.195] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v10/i2/195.htm |
| Number | Citing Articles |
| 1 |
Katsuhiro Matoba, Norio Iizuka, Toshikazu Gondo, Tokuhiro Ishihara, Hisafumi Yamada‐Okabe, Takao Tamesa, Norikazu Takemoto, Kiichiro Hashimoto, Kazuhiko Sakamoto, Takanobu Miyamoto, Shunji Uchimura, Yoshihiko Hamamoto, Masaaki Oka. Tumor HLA‐DR expression linked to early intrahepatic recurrence of hepatocellular carcinoma. International Journal of Cancer 2005; 115(2): 231 doi: 10.1002/ijc.20860
|
| 2 |
Joseph M. Obeid, Paul R. Kunk, Victor M. Zaydfudim, Timothy N. Bullock, Craig L. Slingluff, Osama E. Rahma. Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?. Cancer Immunology, Immunotherapy 2018; 67(2): 161 doi: 10.1007/s00262-017-2082-z
|
| 3 |
Dass S. Vinay, Byoung S. Kwon. 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy. BMB Reports 2014; 47(3): 122 doi: 10.5483/BMBRep.2014.47.3.283
|
| 4 |
Tim F. Greten, Michael P. Manns, Firouzeh Korangy. Immunotherapy of hepatocellular carcinoma. Journal of Hepatology 2006; 45(6): 868 doi: 10.1016/j.jhep.2006.09.004
|
| 5 |
Álvaro Teijeira, Asís Palazón, Saray Garasa, Diego Marré, Cristina Aubá, Anne Rogel, Ohiana Murillo, Iván Martínez‐Forero, François Lang, Ignacio Melero, Ana Rouzaut. CD137 on inflamed lymphatic endothelial cells enhances CCL21‐guided migration of dendritic cells. The FASEB Journal 2012; 26(8): 3380 doi: 10.1096/fj.11-201061
|
| 6 |
Yunqian Qiao, Yangmin Qiu, Jie Ding, Nana Luo, Hao Wang, Xiaomin Ling, Jiya Sun, Zhihai Wu, Yisen Wang, Yanpeng Liu, Feifei Guo, Ta Sun, Wanwan Shen, Min Zhang, Dongdong Wu, Bingliang Chen, Wei Xu, Xuan Wang. Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity. Nature Communications 2021; 12(1) doi: 10.1038/s41467-021-26645-6
|
| 7 |
Lingyun Ye, Keyi Jia, Lei Wang, Wei Li, Bin Chen, Yu Liu, Hao Wang, Sha Zhao, Yayi He, Caicun Zhou. CD137, an attractive candidate for the immunotherapy of lung cancer. Cancer Science 2020; 111(5): 1461 doi: 10.1111/cas.14354
|
| 8 |
Yannick S. Rakké, Sonja I. Buschow, Jan N. M. IJzermans, Dave Sprengers. Engaging stimulatory immune checkpoint interactions in the tumour immune microenvironment of primary liver cancers – how to push the gas after having released the brake. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1357333
|
| 9 |
Dass S. Vinay, Kiweon Cha, Byoung S. Kwon. Dual immunoregulatory pathways of 4-1BB signaling. Journal of Molecular Medicine 2006; 84(9): 726 doi: 10.1007/s00109-006-0072-2
|
| 10 |
Thomas C Wirth. Spontaneous and therapeutic immune responses in hepatocellular carcinoma: implications for current and future immunotherapies. Expert Review of Gastroenterology & Hepatology 2014; 8(1): 101 doi: 10.1586/17474124.2014.862497
|
| 11 |
Angela D Pardee, Amy K Wesa, Walter J Storkus. Integrating costimulatory agonists to optimize immune-based cancer therapies. Immunotherapy 2009; 1(2): 249 doi: 10.2217/1750743X.1.2.249
|
| 12 |
Dass S. Vinay, Byoung S. Kwon. Immunotherapy of Cancer with 4-1BB. Molecular Cancer Therapeutics 2012; 11(5): 1062 doi: 10.1158/1535-7163.MCT-11-0677
|